Dabrafenib plus trametinib in < /i>BRAF< //i> K601E-mutant melanoma

Rogiers, A; Thomas, D; Vander Borght, S; van den Oord, JJ; Bechter, O; Dewaele, M; Rambow, F; Marine, J-C; Wolter, P

doi:10.1111/bjd.17250

Dabrafenib plus trametinib in < /i>BRAF< //i> K601E-mutant melanoma

Author:

Rogiers, A

Thomas, D ; Vander Borght, S ; van den Oord, JJ ; Bechter, O ; Dewaele, M ; Rambow, F ; Marine, J-C ; Wolter, P

Keywords:

Science & Technology, Life Sciences & Biomedicine, Dermatology, BRAF(K601E), Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Humans, Imidazoles, Male, Melanoma, Mice, Mutation, Oximes, Proto-Oncogene Proteins B-raf, Pyridones, Pyrimidinones, Skin, Skin Neoplasms, Treatment Outcome, Xenograft Model Antitumor Assays, 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, Dermatology & Venereal Diseases, 3202 Clinical sciences

Abstract:

About 40 - 50% of cutaneous melanomas have activating BRAF mutations that are reachable with targeted therapy and combined BRAF-MEK inhibition improves clinical outcomes in advanced BRAF V600E/K-mutant melanoma. Three combinations are FDA-approved for this indication: dabrafenib-trametinib, vemurafenib-cobimetinib and encorafenib-binimetinib. The K601E mutation comprises approximately 3% of BRAF mutations in patients with melanoma. This article is protected by copyright. All rights reserved.